-
公开(公告)号:US10710989B2
公开(公告)日:2020-07-14
申请号:US16488770
申请日:2018-02-27
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Makoto Kanematsu , Kazuhisa Ishimoto , Tomoaki Katou
IPC: C07D405/14 , C07D231/12 , C07D405/10
Abstract: The present invention provides a method of producing a heterocyclic compound useful as an agent for the prophylaxis and/or treatment of Alzheimer's disease and the like. The present invention relates to a method of producing 1,5-anhydro-2,4-dideoxy-2-(4-fluoro-5-methyl-1-oxo-6-(4-(1H-pyrazol-1-yl)benzyl)-1,3-dihydro-2H-isoindol-2-yl)-L-threo-pentitol or a salt thereof, which comprises reacting 4-fluoro-3-hydroxy-5-methyl-6-[4-(1H-pyrazol-1-yl)benzyl]-2-benzofuran-1(3H)-one or a salt thereof, 3-fluoro-2-formyl-4-methyl-5-[4-(1H-pyrazol-1-yl)benzyl]benzoic acid or a salt thereof, or a mixture thereof, with 2-amino-1,5-anhydro-2,4-dideoxy-L-threo-pentitol.
-
公开(公告)号:US10668260B2
公开(公告)日:2020-06-02
申请号:US14774385
申请日:2014-03-11
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Yoshihiro Omachi , Yasuhiro Hiraishi , Masami Kusaka , Shigehiro Asano , Masao Nagao
Abstract: The present invention provides a microneedle patch which can solve the problem that microneedle production is difficult and requires high accuracy, the problem that time and mental burdens on a health professional and a patient are large, and the problem caused by compounding a plurality of drugs. The microneedle patch comprises a large number of drug-carrying microprojections 4 erected on one support sheet, each microprojection 4 having a drug layer 5 soluble in vivo at its top part and having an intermediate layer 6 under the drug layer 5, the intermediate layer 6 containing a polymeric substance for adhesion of the drug layer 5 to the support sheet, the drug layer 5 at the top part of the microprojection 4 containing a single drug, the microprojections 4 holding difference types of drugs being arranged together on the support sheet 2.
-
公开(公告)号:US20200148637A1
公开(公告)日:2020-05-14
申请号:US16739707
申请日:2020-01-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKASHI OUCHI , GIHO GOH , SUNMI KIM , JINSOON CHOI , HUNSOO PARK
IPC: C07D207/36 , B01J23/44 , C07B61/00 , C07C253/30 , C07C255/42 , C07D401/12 , C07D207/34 , B01J8/02 , B01J21/04 , B01J29/08 , C07B31/00 , C07B41/06 , C07C255/28
Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.
-
公开(公告)号:US10561662B2
公开(公告)日:2020-02-18
申请号:US16179709
申请日:2018-11-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Stephen Hitchcock , Betty Lam , Holger Monenschein , Holly Reichard
IPC: C07D253/08 , A61K31/53 , A61P25/18
Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
-
135.
公开(公告)号:US10550129B2
公开(公告)日:2020-02-04
申请号:US16381163
申请日:2019-04-11
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Tatsuki Koike , Masato Yoshikawa , Haruhi Ando , William John Farnaby
IPC: C07D498/08 , C07D401/10 , C07D401/14 , C07D405/10 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14
Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号:US10548899B2
公开(公告)日:2020-02-04
申请号:US15769295
申请日:2016-10-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Masaki Ogino , Eiji Kimura , Masataka Murakami , Takuto Kojima , Jinichi Yonemori
IPC: A61K31/53 , A61K31/517 , C07D403/06 , C07D403/10 , C07D405/14 , C07D401/14 , C07D239/88 , C07D401/06 , A61P25/28 , A61P25/04 , A61P25/18 , A61P25/16
Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
-
公开(公告)号:US20190390169A1
公开(公告)日:2019-12-26
申请号:US16490394
申请日:2018-03-02
Applicant: Kyoto University , Takeda Pharmaceutical Company Limited
Inventor: Kenji OSAFUNE , Taro TOYODA , Shiro TAKEKAWA , Goshi NAKAMURA , Ryo ITO
IPC: C12N5/071 , A61K35/545
Abstract: The present invention relates to a method for producing pancreatic progenitor cells from pluripotent stem cells. More specifically, the present invention relates to a method for producing pancreatic progenitor cells, comprising causing the action of a factor having the inhibitory activity for cyclin-dependent kinase 8 and/or cyclin-dependent kinase 19 (hereinafter, also abbreviated to CDK8/19).
-
公开(公告)号:US10508083B2
公开(公告)日:2019-12-17
申请号:US16075240
申请日:2017-02-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Tatsuhiko Fujimoto , Kentaro Rikimaru , Koichiro Fukuda , Hiromichi Sugimoto , Takahiro Matsumoto
IPC: C07D211/36 , A61P25/00
Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
-
公开(公告)号:US10370357B2
公开(公告)日:2019-08-06
申请号:US15899055
申请日:2018-02-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Keisuke Majima
IPC: C07D401/12 , C07D213/71 , A61K9/28 , A61K9/20
Abstract: An object of the present invention is to provide a production method of an intermediate used in the production method of a sulfonylpyrrole compound useful as a pharmaceutical product. The present invention relates to a method of producing sulfonylpyrrole compound (VI) by reacting a pyridine-3-sulfonic acid compound with phosphorus pentachloride in a solvent of chlorobenzene or trifluoromethylbenzene to give a pyridine-3-sulfonyl chloride compound, reacting the compound without isolation with compound (III) to give compound (IV), and subjecting the compound (IV) to a reductive amination reaction. wherein R2 is a hydrocarbon group etc. and R3 and R4 are each a hydrogen atom etc., wherein R2 is an optionally substituted pyridin-3-yl group, and the other symbols are as defined above, wherein R5 is an alkyl group and the other symbols are as defined above.
-
公开(公告)号:US10357484B2
公开(公告)日:2019-07-23
申请号:US15745290
申请日:2016-07-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Akira Kaieda , Masaki Daini , Hiroshi Nara , Masato Yoshikawa , Naoki Ishii , Masashi Toyofuku , Kousuke Hidaka
IPC: A61P25/28 , A61K31/427 , A61K31/437 , A61K31/444 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/4035 , A61K31/4245 , A61K31/4439
Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
-
-
-
-
-
-
-
-